Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CLK2 CRISPR Activation Plasmid (h): sc-403326-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CLK2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- CLK2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CLK2 CRISPR Activation Plasmid (h) and CLK2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CLK2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CLK2 Antibody (F-4): sc-393909
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CLK2 CRISPR Activation Plasmid (h) | sc-403326-ACT | 20 µg | $397.00 |
Human CLK2 (CDC-like kinase 2) is a dual-specificity protein kinase that phosphorylates SR-rich splicing factors and coordinates spliceosome dynamics, linking pre-mRNA processing to transcriptional control. CLK2 activity contributes to alternative splicing programs and intersects with cell cycle regulation and stress-responsive signaling, including pathways affecting RNA metabolism and proteostasis. Dysregulated CLK2 expression or signaling has been associated with altered splicing patterns observed in cancer biology and metabolic disease contexts, making it a useful node for mechanistic studies of RNA processing. As a regulatory kinase, CLK2 provides a tractable handle for dissecting how phosphorylation-dependent splicing decisions reshape downstream gene expression networks.
CLK2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CLK2 expression without altering the underlying DNA sequence.
CLK2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CLK2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CLK2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CLK2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CLK2 locus and enabling the study of CLK2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CLK2 pathway restoration in tumor cells with silenced or reduced CLK2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.